Nociceptin, also known as Orphanin FQ (N/OFQ), is a 17-amino acid endogenous neuropeptide that was discovered in 1995 as the natural ligand for the previously orphan G-protein-coupled receptor now known as the NOP receptor (Nociceptin/Orphanin FQ Peptide receptor). Its discovery resolved the identity of an opioid receptor-like orphan receptor and revealed a novel neuropeptide system distinct from classical opioids. Nociceptin is derived from the precursor protein prepronociceptin and is widely distributed in the central and peripheral nervous systems, with high concentrations in the brain, spinal cord, and adrenal gland.
Despite its structural similarity to dynorphin A and other opioid peptides, nociceptin does not bind with high affinity to classical mu, delta, or kappa opioid receptors. Instead, it acts exclusively through the NOP receptor. The peptide plays a significant role in modulating a diverse array of physiological and pathological processes, including pain perception, stress responses, anxiety, learning and memory, reward, and motor control. Its name, ‘nociceptin’, is somewhat misleading as it can produce both pronociceptive (pain-enhancing) and antinociceptive (pain-reducing) effects depending on the site of administration and the physiological context.
Quick Facts
| Also Known As | Orphanin FQ, N/OFQ, Nociceptin/Orphanin FQ |
|---|---|
| Sequence | FGGFTGARKSARKLANQ |
| Molecular Formula | C79H129N27O22 |
| Molecular Weight | 1809.0 Da |
| PubChem CID | 16131448 |
Research Parameters
| Half-Life | Unknown in humans. In rodent plasma, it is very short, estimated at a few minutes due to rapid enzymatic degradation. |
|---|---|
| Stability | Lyophilized peptide is stable for at least 24 months when stored at -20°C or below, protected from light and moisture. After reconstitution in aqueous buffer (e.g., saline or acetic acid), it is recommended to aliquot and store at -20°C or -80°C to minimize degradation. Stability after reconstitution is protocol-dependent but generally limited to days to weeks even when frozen, due to peptide aggregation and degradation. |
| Solubility | Recommended reconstitution in dilute acetic acid (0.1% v/v in sterile water or saline) to enhance solubility and stability. Bacteriostatic water or sterile saline can also be used, but acidic conditions help prevent aggregation. |
| Vial Size | 1 mg |
| Storage (Lyophilized) | -20°C or below, desiccated, protected from light. |
| Storage (Reconstituted) | Aliquot and store at -20°C or -80°C. Avoid repeated freeze-thaw cycles. Use immediately or within a short period for optimal activity. |
| Typical Research Dose | Research doses vary: 1-10 µg for intrathecal (rodent), 0.18-18 µg for intracerebroventricular (rodent), 100-1000 µg/kg for systemic (IV/SC, rodent). |
| Cycle Parameters | Not applicable for standard research. Preclinical studies typically use acute single-dose administration or short-term chronic administration via osmotic minipump (e.g., 7-14 days of continuous infusion) to model sustained effects. |
| Amino Acid Count | 17 |
Mechanism of Action
Nociceptin exerts its biological effects primarily through selective activation of the NOP receptor (OP4), a G-protein-coupled receptor that shares approximately 60% homology with classical opioid receptors. Upon binding, the NOP receptor couples primarily to Gi/o proteins, leading to inhibition of adenylate cyclase and a reduction in intracellular cAMP levels. This activation also modulates several key ion channels and intracellular signaling pathways, resulting in complex neuromodulatory effects.
Inhibition of Voltage-Gated Calcium Channels: NOP receptor activation inhibits N-type and P/Q-type voltage-gated calcium channels, reducing calcium influx into presynaptic terminals. This suppresses neurotransmitter release (e.g., glutamate, GABA, dopamine) at various synapses, contributing to its modulatory effects on pain transmission, anxiety, and reward.
Activation of Inwardly Rectifying Potassium Channels (GIRKs): The receptor activates G-protein-coupled inwardly rectifying potassium (GIRK) channels, leading to potassium efflux, membrane hyperpolarization, and a decrease in neuronal excitability in postsynaptic neurons. This mechanism is central to its inhibitory actions.
Modulation of Neurotransmitter Systems: Through the above pathways, nociceptin modulates the release of multiple neurotransmitters. It can inhibit the release of excitatory neurotransmitters like glutamate in pain pathways while also inhibiting the release of inhibitory neurotransmitters like GABA, leading to complex, site-specific effects on neural circuits involved in pain, anxiety, and addiction.
Interaction with Stress and Reward Pathways: In the brain, nociceptin acts in regions like the amygdala, hypothalamus, and ventral tegmental area to counteract the effects of stress hormones (e.g., CRF) and modulate dopaminergic activity in the mesolimbic pathway, influencing anxiety-like behaviors, stress responses, and reward processing.
Research Applications
Pain Research: Nociceptin is a major focus in pain research due to its dual modulatory role. Intracerebroventricular administration can produce hyperalgesia or allodynia, while spinal or peripheral administration often produces potent analgesia, especially in neuropathic and inflammatory pain models. Research investigates NOP receptor agonists as potential novel, non-addictive analgesics that lack the respiratory depression and abuse liability associated with classical mu-opioid agonists.
Anxiety and Depression Research: The nociceptin/NOP system is implicated in emotional regulation. Central administration of nociceptin can produce anxiolytic-like effects in some animal models, while NOP receptor antagonists have also shown antidepressant and anxiolytic potential in others. This suggests a complex, tone-dependent role in mood disorders, making it a target for novel psychiatric therapeutics.
Addiction and Reward Research: Nociceptin acts as a functional anti-reward peptide. It attenuates the rewarding effects of drugs of abuse (e.g., morphine, cocaine, alcohol) and reduces dopamine release in reward circuits. Research explores NOP receptor agonists as potential pharmacotherapies for substance use disorders by reducing craving and relapse without the abuse potential of classical opioids.
Motor Control and Neuroprotection: Research indicates involvement in motor control, with potential implications for Parkinson's disease. Additionally, the nociceptin system may have neuroprotective properties in models of cerebral ischemia and excitotoxicity, though these areas require further investigation.
Safety & Side Effects
From animal studies, centrally administered nociceptin can induce several behavioral and physiological effects. Reported effects include motor impairment (ataxia, reduced locomotor activity), sedation, anxiolytic or anxiogenic effects (context-dependent), hyperalgesia or analgesia (site-dependent), and inhibition of gastrointestinal transit. Unlike classical mu-opioids, nociceptin does not typically cause significant respiratory depression at analgesic doses, which is a major research advantage. Anecdotal reports from human research do not exist as it is not used clinically. Theoretical concerns based on its mechanism include potential dysregulation of mood, stress axis, and reward processing. Its safety profile in humans is unknown.
Dosage Information
Disclaimer: The following information is derived from preclinical animal research studies only. It is not intended for human use and does not constitute clinical dosing guidelines.
In rodent research, nociceptin is typically administered via central routes (intracerebroventricular, intrathecal) or peripherally (subcutaneous, intravenous) to study its effects. Doses vary widely depending on the route and model. Common intracerebroventricular doses in mice and rats range from 0.1 to 10 nmol (approximately 0.18 to 18 µg). Intrathecal doses for analgesia studies are often in the 1-10 µg range. Systemic (intravenous or subcutaneous) doses are typically higher, from 0.1 to 1 mg/kg, due to poor blood-brain barrier penetration. Administration is usually acute (single injection) in behavioral studies, though some chronic infusion protocols via minipumps are used to study long-term effects. Frequency and duration are protocol-dependent.
References
Reinscheid, R.K., Nothacker, H.P., Bourson, A., et al. Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor. Science. 1995;270(5237):792-4.
Calo, G., Guerrini, R., Rizzi, A., Salvadori, S., Regoli, D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. British Journal of Pharmacology. 2000;129(7):1261-83.
Mogil, J.S., Grisel, J.E., Reinscheid, R.K., Civelli, O., Belknap, J.K., Grandy, D.K. Orphanin FQ is a functional anti-opioid peptide. Neuroscience. 1996;75(2):333-7.
Lambert, D.G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nature Reviews Drug Discovery. 2008;7(8):694-710.
Gavioli, E.C., Calo, G. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs. Pharmacology & Therapeutics. 2013;140(1):10-25.
Schröder, W., Lambert, D.G., Ko, M.C., Koch, T. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. British Journal of Pharmacology. 2014;171(16):3777-800.
Witkin, J.M., Statnick, M.A., Rorick-Kehn, L.M., et al. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacology & Therapeutics. 2014;141(3):283-99.